araf

Sarafloxacin hydrochloride (A-56620 (hydrochloride)), a quinolone antibiotic drug, is a hydrochloride salt form of sarafloxacin.

Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF with IC50 values of 56, 7, and 5 nM.

Sarafloxacin (A56620) has antibacterial activities against Gram-positive and Gram-negative bacteria.

Sarafotoxin S6d (STX-b) is a peptide toxin isolated from the venom of the Israeli burrowing asp. It induces various Electrocardiogram (ECG) changes such as myocardial ischemia and hyperkalemia. In rat aortas, Sarafotoxin S6d causes intense vasoconstriction dependent on extracellular calcium ions and exhibits positive inotropic effects in rat atria. This compound is useful for research into cardiovascular diseases.

Paraflutizide is a thiazide analog antihypertensive.

Uplarafenib (B-Raf IN 10) is a potent BRAF inhibitor with an IC50 of 50-100 nM. B-Raf IN 10 exhibits antitumor activity that may influence cell proliferation and differentiation, making it suitable for studying solid tumors.

Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 is a biologically active peptide functioning as a selective agonist for Protease Activated Receptor 1 (PAR-1) [a subtype of G-protein coupled receptors involved in mediating thrombin's cellular effects]. Exhibiting high specificity for PAR-1 over PAR-2, its selectivity was assessed via cell-based calcium signaling assays in HEK293 cells. As an agonist, it is instrumental for in vivo investigations of PAR-1 activation. PAR-1 also collaborates with PAR-4, influencing thrombin-induced hepatocellular carcinoma within [coagulation type] tumor environments where thrombin generation occurs.

Ser-parafluoroPhe-Aad-Leu-Arg-Asn-Pro-NH2 is a biologically active peptide. Structure-activity studies of the thrombin receptor-tethered ligand SFLLRNP highlighted the pivotal role of the Phe-2-phenyl group in receptor recognition, while substitution with para-fluorophenylalanine [(p-F)Phe] increased its activity.

[Lys4] Sarafotoxin S6c, an analogue of sarafotoxin, serves as a potent, partial agonist of the endothelin receptor, inducing contraction in pig coronary artery with an effective concentration (EC 50) of 1.5 nM [1].

Belvarafenib TFA (HM95573 TFA) is a potent and broadly available inhibitor of fibrosarcoma kinase (RAF), acting on B-RAF (IC50: 56 nM), B-RAFv600E (IC50: 7 nM), and C-RAF (IC50: 5 nM).

non-selective endothelin receptor agonist

Endothelin receptor agonist (EC50 values are 7.5 and > 150 nM for contraction of pig coronary artery and guinea pig aorta respectively). Nociceptive in vivo.

Exarafenib (RAF KIN_2787) is a potent, orally available pan-RAF inhibitor with antitumor activity that acts by inhibiting downstream MAPK pathway signaling. It is used in cancer research.

Sarafotoxin S6a TFA, an analogue of sarafotoxin, functions as an endothelin receptor agonist with an ET_A ET_B selectivity profile akin to Endothelin-3. It demonstrates an EC_50 of 7.5 nM in stimulating the pig coronary artery [1].

Tarafenacin is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over the M2 receptor.

Paraffin liquid is a useful organic compound for research related to life sciences and the catalog number is T64746.

Sarafloxacin-d8 Hydrochloride is a deuterated compound of Sarafloxacin Hydrochloride. Sarafloxacin Hydrochloride has a CAS number of 91296-87-6. Sarafloxacin hydrochloride, a quinolone antibiotic drug, is a hydrochloride salt form of sarafloxacin.

Tarafenacin D-tartrate (SVT-40776 D-tartrate) is a selective and potent muscarinic acetylcholine M3 receptor antagonist used in the study of overactive bladder and bronchial disorders.

Highly selective ETB endothelin receptor agonist (Ki values are 0.29 and 28000 nM at ETB and ETA receptors respectively).

Brimarafenib is a selective RAF dimerization inhibitor, which can inhibit the activity of BRAF and CRAF, and exhibits significant inhibitory effects on a variety of RAF mutations (including BRAF I II III mutations, BRAF fusion and CRAF heterodimerization), and is used for the treatment of colorectal and pancreatic cancers and other solid tumors with MAPK mutations.

LXH254 is a B C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.

Anticanceragent 250 (compound 104) exhibits antitumor activity by inducing cell apoptosis, slowing proliferation, and degrading key oncogenic proteins such as aRaf and CDK4, without triggering a heat shock response.

alpha-RA-F can modulate collagen synthesis and matrix metalloproteinases (MMPs) expression levels by boosting collagen synthesis and reducing MMPs expression levels in human fibroblasts without cytotoxicity.

Pan-Raf RTK inhibitor 1 (compound I-16) is a potent pan-Raf inhibitor with IC50 values of 3.49 nM (BRafV600E), 8.86 nM (ARaf), 5.78 nM (BRafWT), and 1.65 nM (CRaf). It exhibits antiproliferative activity against various cancer cell lines and can be utilized in cancer research.